A Phase 3 interventional study of Inhaled treprostinil solution and Placebo solution in Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease, sponsored by United Therapeutics. Terminated at 76 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 9th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2018, is one of 15 in phase 3, and was the 29th registered.
1,091 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:
Valley Health System · Sites in United States
Ages 18+
Liquidia Technologies, Inc. · Sites in United States, Australia, Austria and 9 more countries
Ages 18–80
Magdi H. Yacoub · Sites in Egypt
Ages 18+
University of California, San Diego
Ages 18+
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 9
First in 1998; this study’s year is marked. 3 started in 2018.
This study's enrollment of 188 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 32 across the 37 interventional studies. Of the 29 that completed or were terminated, 19 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 38 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
36 studies in Hypertension, Pulmonary by United Therapeutics: 4 open now, 4 under way, 2 of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 36 studies in Hypertension, Pulmonary by United Therapeutics, this one is the 11th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 26th registered.
United Therapeutics’s Hypertension, Pulmonary studies by the year they started, since 1998.
1 of the studies testing treprostinil in Hypertension, Pulmonary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07116681University of California, San DiegoEffects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among United Therapeutics’s 36 in Hypertension, Pulmonary:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks of active treatment in participants with PH-COPD.
This is a multicenter, randomized, double-blind, placebo-controlled, 34-week, cross-over study, with a Treatment Period of approximately 26 weeks under the Original Crossover Design or, if applicable, a 21-week parallel study, with a Treatment Period of approximately 14 weeks under the Contingent Parallel Design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who meet the following criteria may be included in the study:
Males and females 18 years of age and above at the time of informed consent.
Clinical diagnosis of COPD will be made using the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) diagnostic criteria (GOLD Criteria 2020) and spirometry with the following documented parameters measured during Screening Visit 1 (prior to start of low-dose inhaled treprostinil):
Have a right heart catheterization (RHC) performed during Screening Visit 1. (A previous RHC obtained within 12 months prior to the start of Screening Visit 1 is acceptable for determining eligibility, even if done without oxygen or vasodilator challenge, and a repeat RHC is not required.) The following parameters must be documented for eligibility:
Exclusion Criteria:
The following will exclude participants from the study:
Based on chest computed tomography (CT) imaging during Screening Visit 1, the participant has a confirmed diagnosis of WHO Group 3 PH, other than COPD, such as idiopathic pulmonary fibrosis, combined pulmonary fibrosis and emphysema, diffuse parenchymal lung disease or interstitial lung disease. A previous chest CT scan performed within the 6 months prior to the start of Screening Visit 1 is also acceptable, and a repeat assessment is not required.
A redacted CT scan report (from Screening Visit 1 or dated within prior 6 months) should be provided to the Medical Monitor with the Pre-Baseline Review Form to confirm eligibility.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inhaled treprostinil delivered via an ultrasonic nebulizer with a target dosing regimen of 12 breaths (72 micrograms \[mcg\]) 4 times daily (QID)
Drug: Inhaled treprostinil solution
Placebo delivered via an ultrasonic nebulizer for QID administration
Drug: Placebo solution
Treprostinil inhalation solution
Placebo solution
Change From Baseline to Week 12 in 6-Minute Walk Distance (6MWD)
6 MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded. Statistical analyses were not performed due to lack of appropriate sample size.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in Moderate to Vigorous Physical Activity (MVPA)
MVPA was defined as the number of minutes spent in moderate to vigorous physical activity as measured via a wrist-worn medical grade physical activity monitor. The screening data were used to establish a baseline level of physical activity.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in Overall Activity
Overall activity was defined as the number of minutes spent in overall activity (non-sedentary activity) as measured via a wrist-worn medical grade physical activity monitor. The screening data will be used to establish a baseline level of physical activity.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in Borg Dyspnea Score
The Borg Dyspnea Score was a 11-point scale rating the maximum level of dyspnea experienced during the 6-minute walking test (6MWT). Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating a less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in 6MWD/Borg Dyspnea Composite Score
6MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded. The Borg Dyspnea Score was an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT. The average 6WMWD data and the average Borg Dyspnea Composite Score data were summed and reported as the composite score.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in Quality of Life (QOL) Measured by St. George's Respiratory Questionnaire (SGRQ)
The SGRQ is a designed to measure how breathing impacts overall health, daily life, and perceived well-being in participants with obstructive airways disease. Scores range from 0 to 100, with lower scores indicating a better QoL.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in QOL Measured by the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)
The UCSD SOBQ is a self-administered rating of dyspnea associated with activities of daily living. The questionnaire uses a 6-point scale where 0 = "not at all" and 5 = "maximal or unable to do because of breathlessness". Lower scores indicate a better QoL.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in Plasma Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels
The NT-proBNP concentration is a biomarker associated with changes in right heart morphology and function. Improvement is defined as a decrease in the NT-proBNP plasma concentration.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in Patient Global Assessment (PGA)
The PGA is used to rate participant fatigue and shortness of breath. Participants will use the Sponsor-provided smart device for at-home capture of PGA data. The PGA used a 5-point response scale of: "never," "rarely," "sometimes," "often," or "always" with higher scores indicating a worse symptom rating.
Time frame: Baseline, Week 12
188 participants were enrolled; 80 of the 188 enrolled participants were screen failures prior to the Run-In Period. Per prespecified analysis, data were not collected for the participants who were screen failures.
| Milestone | Run-In | Original Crossover Design - Treprostinil, Then Placebo | Original Crossover Design - Placebo, Then Treprostinil | Contingent Parallel Design - Treprostinil | Contingent Parallel Design - Placebo |
|---|---|---|---|---|---|
| Started | 108 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 108 | 0 | 0 | 0 | 0 |
| Completed | 76 | 0 | 0 | 0 | 0 |
| Not completed | 32 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Discontinued prior to randomization | 31 | 0 | 0 | 0 | 0 |
| Milestone | Run-In | Original Crossover Design - Treprostinil, Then Placebo | Original Crossover Design - Placebo, Then Treprostinil | Contingent Parallel Design - Treprostinil | Contingent Parallel Design - Placebo |
|---|---|---|---|---|---|
| Started | 0 | 32 | 32 | 6 | 6 |
| Received at least 1 dose of study drug | 0 | 32 | 32 | 6 | 6 |
| Completed | 0 | 26 | 29 | 5 | 4 |
| Not completed | 0 | 6 | 3 | 1 | 2 |
| Withdrew: Death | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 3 | 3 | 0 | 0 |
| Milestone | Run-In | Original Crossover Design - Treprostinil, Then Placebo | Original Crossover Design - Placebo, Then Treprostinil | Contingent Parallel Design - Treprostinil | Contingent Parallel Design - Placebo |
|---|---|---|---|---|---|
| Started | 0 | 26 | 29 | 0 | 0 |
| Received at least 1 dose of study drug | 0 | 20 | 28 | 0 | 0 |
| Completed | 0 | 19 | 21 | 0 | 0 |
| Not completed | 0 | 7 | 8 | 0 | 0 |
| Withdrew: Covid-19 pandemic impact | 0 | 4 | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 1 | 0 | 0 |
6 MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded. Statistical analyses were not performed due to lack of appropriate sample size.
| meters | Original Crossover Design - Treprostinil | Original Crossover Design - Placebo | Contingent Parallel Design - Treprostinil | Contingent Parallel Design - Placebo |
|---|---|---|---|---|
| Baseline | 225.07 ± 77.41 | 220.47 ± 77.64 | 231.50 ± 60.77 | 283.00 ± 67.78 |
| Change at Week 12 | -4.47 ± 39.01 | -5.14 ± 50.71 | 20.33 ± 116.99 | 18.5 ± 42.49 |
MVPA was defined as the number of minutes spent in moderate to vigorous physical activity as measured via a wrist-worn medical grade physical activity monitor. The screening data were used to establish a baseline level of physical activity.
No measurements were reported for this outcome.
Overall activity was defined as the number of minutes spent in overall activity (non-sedentary activity) as measured via a wrist-worn medical grade physical activity monitor. The screening data will be used to establish a baseline level of physical activity.
No measurements were reported for this outcome.
The Borg Dyspnea Score was a 11-point scale rating the maximum level of dyspnea experienced during the 6-minute walking test (6MWT). Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating a less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT.
No measurements were reported for this outcome.
6MWD was calculated at peak exposure (10 to 60 minutes after dosing). 6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course for 6 minutes (timed) and the distance walked (in meters) was recorded. The Borg Dyspnea Score was an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea), with lower scores indicating less exertion (a better outcome). The Borg Dyspnea Score was to be evaluated immediately after the 6MWT. The average 6WMWD data and the average Borg Dyspnea Composite Score data were summed and reported as the composite score.
No measurements were reported for this outcome.
The SGRQ is a designed to measure how breathing impacts overall health, daily life, and perceived well-being in participants with obstructive airways disease. Scores range from 0 to 100, with lower scores indicating a better QoL.
No measurements were reported for this outcome.
The UCSD SOBQ is a self-administered rating of dyspnea associated with activities of daily living. The questionnaire uses a 6-point scale where 0 = "not at all" and 5 = "maximal or unable to do because of breathlessness". Lower scores indicate a better QoL.
No measurements were reported for this outcome.
The NT-proBNP concentration is a biomarker associated with changes in right heart morphology and function. Improvement is defined as a decrease in the NT-proBNP plasma concentration.
No measurements were reported for this outcome.
The PGA is used to rate participant fatigue and shortness of breath. Participants will use the Sponsor-provided smart device for at-home capture of PGA data. The PGA used a 5-point response scale of: "never," "rarely," "sometimes," "often," or "always" with higher scores indicating a worse symptom rating.
No measurements were reported for this outcome.
Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-In | 1/108 (0.9%) | 9/108 (8.3%) | 50/108 (46.3%) |
| Treprostinil | 5/66 (7.6%) | 17/66 (25.8%) | 36/66 (54.5%) |
| Placebo | 0/58 (0%) | 6/58 (10.3%) | 25/58 (43.1%) |
| Event | Run-In | Treprostinil | Placebo |
|---|---|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/108 | 0/66 | 3/58 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/108 | 3/66 | 1/58 |
| Acute myocardial infarctionCardiac disorders | 0/108 | 0/66 | 2/58 |
| AnaemiaBlood and lymphatic system disorders | 0/108 | 0/66 | 1/58 |
| Atrial fibrillationCardiac disorders | 0/108 | 0/66 | 1/58 |
| Cardiac failure acuteCardiac disorders | 1/108 | 0/66 | 1/58 |
| Cardiogenic shockCardiac disorders | 0/108 | 0/66 | 1/58 |
| Pulseless electrical activityCardiac disorders | 0/108 | 0/66 | 1/58 |
| Ischaemic hepatitisHepatobiliary disorders | 0/108 | 0/66 | 1/58 |
| PneumoniaInfections and infestations | 0/108 | 1/66 | 1/58 |
| Event | Run-In | Treprostinil | Placebo |
|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 19/108 | 19/66 | 9/58 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/108 | 11/66 | 3/58 |
| FatigueGeneral disorders | 2/108 | 7/66 | 2/58 |
| HeadacheNervous system disorders | 9/108 | 7/66 | 4/58 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 9/108 | 3/66 | 2/58 |
| Chest discomfortGeneral disorders | 3/108 | 5/66 | 0/58 |
| Upper respiratory tract infectionInfections and infestations | 1/108 | 2/66 | 4/58 |
| DizzinessNervous system disorders | 2/108 | 4/66 | 2/58 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 5/108 | 4/66 | 2/58 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/108 | 2/66 | 3/58 |
Full Analysis Set included all participants who were randomized and received at least one dose of study drug.
| Age, Continuous(years) | Original Crossover Design | Contingent Parallel Design - Treprostinil | Contingent Parallel Design - Placebo | Total |
|---|---|---|---|---|
| Mean | 67.6 ± 7.83 | 70.3 ± 6.71 | 73.3 ± 2.16 | 69.7 ± 8.01 |
| Sex: Female, Male(Participants) | Original Crossover Design | Contingent Parallel Design - Treprostinil | Contingent Parallel Design - Placebo | Total |
|---|---|---|---|---|
| Female | 31 | 0 | 2 | 33 |
| Male | 33 | 6 | 4 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Original Crossover Design | Contingent Parallel Design - Treprostinil | Contingent Parallel Design - Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 | 4 |
| Not Hispanic or Latino | 62 | 6 | 4 | 72 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Original Crossover Design | Contingent Parallel Design - Treprostinil | Contingent Parallel Design - Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 15 | 1 | 2 | 18 |
| White | 47 | 5 | 4 | 56 |
| More than one race | 2 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2018 to primary completion in Oct 2022, 53 months.
Results were first posted in Nov 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil